Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.38 |
| ▸ | PDE5A | O76074 | 2/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618266 | 0.97 | HDAC6 (0.35) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3602422 | 0.76 | PDE5A (0.42) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3602430 | 0.75 | HDAC6 (0.38) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3602419 | 0.73 | PDE5A (0.46) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3604245 | 0.72 | MEN1 (0.46) | — | |
| SCHEMBL3618263 | 0.72 | PDE5A (0.39) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3618272 | 0.71 | HDAC6 (0.35) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3610532 | 0.70 | HDAC1 (0.46) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL3600706 | 0.69 | PDE5A (0.43) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL5602775 | 0.68 | PDE5A (0.62) | HDAC6HDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | HDAC6 90/4885HDAC1 307/4885HDAC3 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.